Practical Implementation of TG 263's Standardized Nomenclatures Across Multiple Radiation Oncology Practices



Carnell Hampton, PhD, DABR

Nomenclature and Big Data – TG 263 and the Future 2019 AAPM Spring Clincal Meeting March 2019 At the conclusion of this presentation, the participant will be able to:

- Describe Task Group 263's goals and recommendations
- Review clinical examples and receive guidance for gaining efficiencies across multiple software platforms used during the radiation therapy process across a multi-facility practice
- Explore the use of metrics designed to quantify efficiency gains realized by implementing the Task Group's recommendations



Disclosures

• None

Date of the Party

WHERE A

This Photo by Unknown Author is licensed under CC BY-SA


B N N N N N N

1.1.1.1.1.1.1.1




- Why Standardize?
- Challenges in a multifacility community-based practice
- Case Study: Standardized Clinical Treatment Planning Standards
 - SBRT Lung

















LCI Rad Therapy By the Numbers:

9 physical locations

6 single-linac facilities & 3 multiplelinac sites

350+ patients daily

> 2000 special procedures annually

Multisite American College of Radiology (ACR) Accreditation

AAPM Task Group 263

- Report issued in 2017
- 57 stakeholders
 - Physicists, Physicians, Dosimetrists, Members of Cooperative group trials, AAPM, DICOM working group, ASTRO, IHE-RO
- Develop consensus position on nomenclature for use in clinical trials, datapooling initiatives, populations-based studies and routine clinical care by standardizing:
 - Structure names across platforms
 - Nomenclature for dosimetric data
 - Templates for clinical trials groups and users
 - Formalism for nomenclature schema for the future

International Journal of Radiation Oncology biology • physics

www.redjournal.or

CrossMark

Critical Review

American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology

Charles S. Mayo, PhD,* Jean M. Moran, PhD,* Walter Bosch, PhD,† Ying Xiao, PhD,[‡] Todd McNutt, PhD,[§] Richard Popple, PhD,[®] Jeff Michalski, MD,[†] Mary Feng, MD,[¶] Lawrence B. Marks, MD, PhD,[#] Clifton D. Fuller, MD, PhD,** Ellen Yorke, PhD,^{††} Jatinder Palta, PhD,^{‡‡} Peter E. Gabriel, MD,[‡] Andrea Molineu, MS,** Martha M. Matuszak, PhD,* Elizabeth Covington, PhD, Kathryn Masi, PhD,⁵⁸ Susan L. Richardson, PhD,¹¹¹ Timothy Ritter, PhD,^{##} Tomasz Morgas, *** Stella Flampouri, PhD, T Lakshmi Santanam, PhD, Joseph A. Moore, PhD,[§] Thomas G. Purdie, PhD,^{‡‡} Robert C. Miller, MD, 555 Coen Hurkmans, PhD, Judy Adams, MS, ### Qing-Rong Jackie Wu, PhD, **** Colleen J. Fox, PhD, Ramon Alfredo Siochi, PhD,¹¹¹¹ Norman L. Brown, HScD,⁸⁶⁸⁸ Wilko Verbakel, PhD, Yves Archambault, MS,*** Steven J. Chmura, #### Andre L. Dekker, ***** Don G. Eagle, MS, ***** Thomas J. Fitzgerald, MD,¹¹¹¹¹ Theodore Hong, MD,¹¹¹ Rishabh Kapoor, MS,^{‡‡} Beth Lansing,^{§§§§§} Shruti Jolly, MD,* Mary E. Napolitano, PhD, James Percy, SSSSS Mark S. Rose, MS, Salim Siddigui, MD, ##### Christof Schadt, ****** William E. Simon, MS, ##### William L. Straube, Sara T. St. James, PhD,¹¹¹¹¹¹ Kenneth Ulin, PhD,¹ Sue S. Yom, MD, PhD,[¶] and Torunn I. Yock, MD, MCH^{###}

*University of Michigan, Ann Arbor, Michigan; ¹Washington University, St. Louis, Missouri; ¹University of Pennsylvania, Philadelphia, Pennsylvania; ¹Johns Hopkins University, Baltimore,

Reprint requests to: Charles S. Mayo, PhD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109. Tel: (734) 232-3837; E-mail: cmayo@med.umich.edu Conflict of interest: Dr Molineu reports grants from the National conduct of the study. Dr Bosch reports grants from the US National Institutes of Health, during the conduct of the study. Supplementary material for this article can be found at www.redjournal.org.

Why Standardize?

- Clarity in communication among team members
 - Are we talking about the same things?
 - Is our INTENT clear?
 - Are we using AMBIGUOUS methods of communicating?

 Table 1. Variations in standardized nomenclatures reported for non-target structures by 16 institutions.

 The number in () indicates the number of respondents using the same value if > 1.

Structure	Number of Institutions	Examples		
Left Optic Nerve	12	Lt Optic Nerve, OPTICN_L, OPTNRV_L, optic_nrv_l, L_optic_nerve, OPTIC_NRV_L, OpticNerve_L, LOPTIC, OpticNerve_L (3), Lef Optic Nerve, ON_L		
Left Lung	12	Lt Lung, Lung_L(4), LUNG_L(3), lung_I, L_lung, LLUNG, L Lung		
Both Lungs	12	Lungs(2), LUNGs, LUNG_TOTAL, lung_total, combined_lung, LUNG, LUNGS(2), Lung,BilatLung, Lung_Both		
8th Cranial Nerve	7	CN_VIII(5), cn_viii(2), CN8, CN_8		
Right External Iliac Artery	2	A_ILIAC_E_R, a_iliac_e_r		

Why Standardize?

Clarity in communication among systems	CT Scanners EMRs Treatment Delivery systems Image management systems
Sometimes OUr systems don't cooperate	Character limits Case sensitivity Incompatible characters ^, *, #, '

A kick in the pants...

Multisite ACR re-accreditation in 2016

ACR-ASTRO Practice Guidelines

- Define the goals and requirements of the treatment plan, including the specific dose constraints for the target(s) and nearby critical structure(s).
- Delineate tumor and specify and approve target volumes, preferably using appropriate methodology of the International Commission on Radiation Units and Measurements (ICRU).
- Review and approve all critical structures contoured. Perform final evaluation and approve the final IMRT plan for implementation
- Additional recommendation to specify goals and "close the loop" by recording results of planning process
- This was an opportunity...

- Automation
- Solution needed to be deployable across multiple sites
- Configuration allowed for standardization to be encouraged/enforced

Constraint Template		LCI LungSBRT - 50Gy in 5fx Prescriptions								Constraints DVH Structure Check	
LCI_LungSBRT					Prescr	iption Total Dose					🗸 Margin Checks
					Lung	SBRT 6000					Plan Checks
an Check Template											
					LCI LungSBRT -	50Gy in 5fx Constraints					
leport Template		Structure	Charles								1
Aria Report IMRT_SBR Y	Priority	Template	Structure Plan	Туре	Prescription	Constraint	Goal	Left Lung	Pass/Fail	Comment	
	1	PTV	PTV01	Target		V5000cGy ≥	95%	100%	~		
	2	PTV	PTV01	Target	Lung SBRT: 6000cGy	D99% ≥	90%	97.293%	1		
c2	3	PTV	PTV01	Target	Lung SBRT: 6000cGy	Max ≤	160%	115.517%	1		
an	4	PTV	PTV01	Target	Lung SBRT: 6000cGy	(RTOG Homogeneity Index) RHI 100% \leq	1.11-1.67	1.155	Δ		
Left Lung 🗸	5	PTV	PTV01	Target	Lung SBRT: 6000cGy	(V105% < PTV15%) Dose Spill V105% \leq	15%	0.262%	~		
	6	PTV	PTV01	Target	Lung SBRT: 6000cGy	(Conformality Index) CI 100% \leq	1.2-1.5	0.994	~		
ose eft Lung	7	PTV	PTV01	Target	Lung SBRT: 6000cGy	(R50%) CI 50% ≤	4.127-5.127	4.761	Δ		
1200cGy x 5 = 6000cGy	8	ITV	ITV	Target		V5000cGy ≥	100%	100%	~		
	9	Body-PTV+2cm	Body-PTV+2	OAR	Lung SBRT: 6000cGy	(D2cm) MaxDT using PTV01 volume ≤	60.3-73.175%	73.846%	×	JH	
Report	10	Spinal Cord	SpinalCord	OAR		V2200cGy ≤	0.35cc	Occ	~		
	11	Spinal Cord	SpinalCord	OAR		D0.035cc ≤	2800cGy	1017.8cGy	~		

ClearCheck

- ClearCheck is a script that is integrated into the Eclipse treatment planning software that provides plan quality assurance functionality
- Made optimally efficient through the matching of planning structures and a template
- TG-263 Standardized nomenclature can easily be incorporated into templates



	*****	-1,	· · · · ·	e Net Anne Pythone Petrology Anne	nda Anata Sala Anata	10 De La Santa - Jy D an her her for the Santa - Jy D to Mark - Santa - Jy D	
	A provide the second se			Alternational and a second sec	Ame The second sec		




- Principles for non-target, target nomenclature
- Recommendations for DVH Metrics
- Implementation
- Nomenclature spreadsheet
 - >700 structure names
- Eclipse structure templates

TG-263 Resources

https://www.aapm.org/pubs/re ports/RPT_263_Supplemental/ Will my dosimetrists, physicists and oncologists EMBRACE standardization?



https://www.google.com/url?sa=i&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjzrrHO85XhAhWLTd8KHaDLAz0QjB16BAgBEAQ&url=https%3A%2F%2Fw ww.winshuttle.com%2Fblog%2Fshared-services-process-standardization%2F&psig=AOvVaw1UI4gjhho9fcTy1-J8vci5&ust=1553345806268298



Environmental Challenges

Regional practices

Varied environments

Lean staffing Vs Academic practice

Rotating Coverage

LCI LungSBRT -

Pres

Lund

Technology Challenges LungSBRT - 5

tructure Structure Type Prescription Multiple vendor environment emplate PTV 95% • 3 different EMRs – Varian ARIA 15.1, Varian Lung SBRT: 6000cGy PTV D99% ≥ 90% ARIA 13.6, Mosaiq • 3 different TPS – Varian Eclipse 15.1, Varian PTV 160% (RTOG Homogeneity -1.67PTV Eclipse 13.6, Raysearch Raystation PTV Lung SBRT: 6000cGy (V105%<PTV1 • 2nd Check Software – Radcalc Lung SBRT: 6000cGy PTV DVH & Objective Analysis Software – Lung SBRT: 6000cGy PTV ClearCheck ITV Target Image Management Database – MIM Maestro /-PTV+2cm (D2cn inal Cord SpinalCord OAR inal Cord SpinalCord OAR

Develop Implementation Plan


- Define goal
 - Realize efficiencies in the planning and plan documentation processes
 - Enhance safety by standardizing nomenclature
 - Demonstrate utilization and compliance with standards in all clinics
- Leading measure
 - Feedback/participation in weekly implementation meetings

Communication

- Communicate with all stakeholders the broad goal of standardization
- Provide documentation

Camplines Heat

LCI Radiation C Continuous Q Assurance Com




- Provide training
- Selectively introduce at robust clinical site
- Identify champions
- Develop best practices for workflows, protocols
- Gather feedback from smaller groups

Pilot Implementations

Expansion

- Introduce templates, workflows, protocols at a second rad therapy clinic
- Promote champion's experience
- Incorporate key lessons learned



Feedback

- Understand small process differences from clinic to clinic
- Identify roadbacks to implementation
- Perform necessary revisions
- Allow constrained creativity

		Max Do	se		сGу	
		Total Num	ber of			
		Beam	ITV Dimensions PTV Volume	6.1	mm R _{50%} cc V _{Rx leodose/} V _{PTV}	5.2 1.2
		Tota	PTV Dimensions Total Rx Dose	5400 cGy	mm D _{2cm} Max Daily Daily	Dose 2630 cGy
Radiotherapy Prescription			# of fractions	3	PTV Rx isodose Coverage	e (V _{Rx}) 95.0 %
			V _{50%RxExternal} V _{Rx} isodoseExternal	27.9 cc 6.8 cc	Max D _{99%} D _{95%}	
Dose per Fraction Total Dose	18 6	iy x 3 5	V 105%Non-target tissue	, <mark>0.6</mark> cc	D ₁₀₀	@ ^{2cm*} 2174 cGy ‰ITV <u>6427</u> cGy ≿ Dose 40 %
Implementation		e close t	V _{Rx i800089} ÷ V _{PTV} V _{50%Rx} Iso ÷ V _{PTV} D _{max} @ 2cm (% of Rx Dose) V _{105%} ≤ PTV _{15%}	4.6 Compliant	$\begin{array}{l} D_{95\%} PTV \geq 90\% \ Rx \ Isodose? \\ D_{55\%} PTV \geq Rx \ Isodose? \\ D_{100\%} ITV \geq Rx \ Isodose? \end{array}$	Compliant Compliant Compliant
of Standardized	/olume Receiving	Dose	Comments			
Organ	Tolerance (cc)) To	lerance		fx)	
spinal & Planning	0	ĉ	Goal		1590	
-Standards.	530				2250	
Ips. Brachial Plexus		•	Impleme	ent Clear	Check as co	nsistent
LUNgmSBR (CGy)			quality g	soal attaii	Check as co ; OAR and ta nment	aiget platt
Lung (Right and Left) Volume:	4557				of consisten	
∨ 1080	315		nomenc	lature for	r all treatme	ent plans
	4242	•	Eliminat	e use of r	multiple spi	readsheets
∨ 1140	303			al plan so	coring shee	ts
Lanza Davashi	7%		<37%		1140	
Large Bronchi			<5cc		3900	
Maximum Dose (cGy)					4300	
Heart	0		< 15cc		2400	

Practical Radiation Oncology (2019) 9, 65-72




Special Article

Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: An ASTRO Consensus Paper

Jean L. Wright MD^a, Sue S. Yom MD, PhD, MAS^b, Musaddiq J. Awan MD^c, Samantha Dawes CMD^d,*, Benjamin Fischer-Valuck MD^e, Randi Kudner MA^d, `aymond Mailhot Vega MD, MPH^f, George Rodrigues MD, PhD^g

⁴opkins University, Baltimore, Maryland; ^bUniversity of California, San Francisco, Calif ⁱⁿ, Milwaukee, Wisconsin; ^dAmerican Society for Radiation Oncology, Arlington, V ⁱⁿ; ^fUniversity of Florida, Jacksonville, Florida; ⁸London Health Science

revised 29 November 2018; accepted 8 December 2018



wention for tissue labels in this table align with American Association of Physicists in Medicine Task Group. Nomenclasse et in Radiation Oncology; [5]

	Thoracic	
Treated Organ	Recommended	Consider
	Heart	A_LAD
	Lung_L/R	BrachialPlex_L/R
Breast/Chestwall		Breast (contralateral)
breasty chestwow		Lungs
		Ribs
		Ventricle_L
	Lung_L/R	BrachialPlex_L/R
Supraclavicular Fossa	SpinalCord	Esophagus
300100011000110330		Gin d_Thyroid
		Lungs
	Heart	BrachialPlex_L/R
Axila	Lung_L/R	Esophagus
Carlle	SpinalCord	Gin d_Thyroid
		Lungs
	Esophagus	A_LAD
	Heart	BrachialPlex_L/R
	Lung_L/R	Bronchus_L/R
	Lungs	Bronchus_Main
Lung	SpinalCord	Chest wall_L/R
		Great Ves
		Liver
		Stomach
		Trachea
	Esophagus	A_LAD
	Heart	Bronchus_Main
Mediasti num/Th ymus	Lung_L/R	Trachea
	Lungs	
	SpinalCord	
	Esophagus	Kid ney_L/R
	Heart	Kidneys
	Lung_L/R	Larynx
	Lungs	Liver
	Spin al Cord	
	Stomach	

Methods

Create Standard for all LCI Clinics

- Download Eclipse template from TG-263 resource page, Import into Eclipse V15.1 and customize:
 - Inclusive of ASTRO consensus OARs
 - Consensus of names for planning structures
 - TG suggested target nomenclature
- Export configured Eclipse Structure Template and import into Eclipse V13.6

Filter

Global Templates

	Tanadata	Anthur	
	Template	Active	
#	LCI LungSBRT - 50Gy in 5f	✓	-
Ħ	LCI LungSBRT - 54Gy in 3f	\checkmark	
Ħ	LCI_LungSBRT - 50Gy in 41	~	
Ħ	LCI_HA-WBRT	 Image: A set of the set of the	
Ħ	LCI_Prostate-Hypo	~	
H	LCI_Prostate-SBRT	~	
I	LCI_Prostate-Standard	~	
H	Default 3D	~	
I	Breast 3D	~	
Ħ	Whole Brain	~	
I	Breast e- Boost	~	
Ħ	Lung SBRT - 50Gy in 5fx		
Ħ	Lung SBRT - 50Gy in 4fx		
I	Lung SBRT - 54Gy in 3fx		
	Total Prostate 79Gy	~	
:	Boost Prostate 28.8Gy	~	
I	Prostate/SV 45Gy	~	
I	Boost Prostate 34.2Gy	~	
I	Total Prostate 79.2Gy	~	
I	RTOG 0631 Spine	~	
Ħ	H&N 70Gy		
H	H&N - 3 dose levels RH	~	

+ \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc

LCI LungSBRT - 50Gy in 5fx Prescriptions

Prescription Total Dose

Lung SBRT 5000

τı	

H


LCI LungSBRT - 50Gy in 5fx Constraints

	Priority	Structure	Aliases	Туре	Prescription		Constraint Type	Constraint	Сог
I	1	PTV	PTV_5000, PTV01	Target ~	·	Vo	vilume v	V5000cGy>95%	
#	2	PTV	PTV_5000, PTV01	Target ~	Lung SBRT: 5000cGy	* Do	ose 🗸	D99%>90%	
Ħ	3	PTV	PTV_5000, PTV01	Target ~	Lung SBRT: 5000cGy	• M	хе хе	Max<160%	
Ħ	4	PTV	PTV_5000, PTV01	Target 🗸	Lung SBRT: 5000cGy	~ RT	OG HI v	RHI100%	RTO G Hon Index
Ħ	5	PTV	PTV_5000, PTV01	Target ~	Lung SBRT: 5000cGy	Y Do	ose Spill	nfigure	V105% <p1< td=""></p1<>
Ħ	6	PTV	PTV_5000, PTV01	Target ~	Lung SBRT: 5000cGy	~ CI			Conformal
Ħ	7	PTV	PTV_5000, PTV01	Target ~	Lung SBRT: 5000cGy	~ CI		arCheck	R50%
#	8	ITV	ITV	Target ~	·				
Ħ	9	Body-PTV+2cm	Body-PTV+2cm	OAR ~	Lung SBRT: 5000cGy	~ M		nplates	D2cm
H	10	Spinal Cord	SpinalCord, Cord	OAR ~	•	Vo	lume ICI		
:	11	Spinal Cord	SpinalCord, Cord	OAR ~	•		ose 🗸	D0.035cc<2800cGy	
I	12	SpinalCanal	SpinalCanal	OAR ~	·	Use	TG-263 star	ndardized nomen	clature
:	13	SpinalCanal	SpinalCanal	OAR ~	•	Do	exactly	<pre>/ matching TPS</pre>	
:	14	Brachial_Plex_R	Brachial_Plex_R, Rt	OAR 🗸	,	Do	^{se} No ně	ed for aliases!	
+ [Ì 🗇	Structure Check	Cemplate LCI_LungSBRT	v Notes:			ave reviewed each specified	metric. Goals not achieved are noted in re	
		Plan Check 1	emplate	~	meaningful in this case.	s nom my pre	-specified goals are accepta	ble and appropriate in order to prioritize o	other goals tel t to be
		Report	Template Aria Report IMR	T_ *					

Process Refinement

- 3-week "trial" implementation
- All sites encouraged to use clinically
- Record feedback in worksheet
- Weekly Skype meetings with users to demonstrate functionality, answer questions and review feedback

Standardized Nomenclature Feedback Tool Please provide feedback about items missing from either the Eclipse Template or ClearCheck							
	Please provide feedback about items missing from	m either the Eclipse Template or ClearCheck					
Product	Comment	User - Please Enter Name	Addressed; pericardium has same constraints				
ClearCheck	Please add the Spinal Canal, small airway, Pericardium		as heart. Changed cc name from "heart" to "heart/pericard"				
Eclipse Template	Can PTVs be changed to translucent or contour? Our physicians do not like segment when looking at targets on CBCT	Romeo Boulet	Addressed; changed targets to translucent				
ClearCheck SBRT Lung	The margin check is not in the print report template for SBRT lung. It is also not configured, standard is a 5 mm PTV expansion from the ITV.	Mark DiMascio	Addressed; added margin check for ITV->PTV expansion and added to report template				
ClearCheck	What should be done about constraints objectives that are not met		MDs should initial constraints that are unment during plan review. Standard language added to all cc templates.				
ClearCheck	Better explaination for plan quality metrics	Ben Moeller/Ryan Foster	familiar nomenclature added as comments in template which print on final pdf				
ClearCheck	It may be beneficial to add a rib contour to the template and constraints; we reference RTOG and Timmerman rib guidelines when annlicable	Nina Bahar	added Rib V3000cGy<30cc				
ClearCheck	It may be beneficial to add a rib contour to the template and constraints; we reference RTOG and Timmerman rib	Nina Bahar	added Rib V3000cGy<30cc				



Results: Efficiency Metric

	Description	Standardized Plan/Template	Manually Matched OAR Names	Manually Recorded from Eclipse DVH
Case #1 – SBRT (New User)		1 min 2 secs	1 min 53 sec	N/A
Case #1 – SBRT (Experienced User)	23 PTV/OAR	0.32 secs	0.43 sec	5min 55 sec
Case #2 - IMRT Brain (new user)	11 PTV/OAR	N/A	1 min 3 secs	2min 12 secs
Case #1 – IMRT Brain (exp. user)	IIII WOAK	N/A	1 min	1min 45 secs

Results: Structure Naming Variation

LCI Before Standardization


- Lung_Lt, Lung L
- Aorta, large vessels, Great Vessels
- Bronchus_LT
- Small Airway, proximal bronch
- Spinal Cord, cord
- Total Lung
- Skin, Skin_dvh
- Brachial plexus
- Chest wall, chestwall

LCI After TG-263 Standardization

- Lung_L
- GreatVes
- Bronchus_Main
- AirWay_Prox
- SpinalCord
- Lungs, Lungs-ITV
- Skin
- BrachialPlex
- Chestwall

Results: Technique Adoption

- 4 of 9 practices deliver SBRT
- 100% utilization rate for ClearCheck matching to templates with standardized OAR nomenclature



Extension to Other Software Platforms

TG-263 Standardized Nomenclature

RadCalc - Piedmont Carolir				
<u>F</u> ile <u>W</u> indow <u>H</u> elp				
Piedmont Carolinas Radiation Therapy 💌	eogin/Logout Previous	Next Open	-	 -Do
titution Setup - Regions of Inter	rest Options		_	
Add ROIs from patient files				

gions of Interest Defaults

ROI Name	Density	Visible by default	Do not import	Pseudonyms
AirWay_Prox	0.500	✓		
Bones	1.200	✓		
Chestwall	1.000	✓	✓	
CouchInterior	0.250	✓		CouchInterior1
CouchSurface	0.700	✓		CouchSurface1
Esophagus	0.500	✓		
GreatVes	1.000	✓	✓	
Heart	1.000	✓	✓	
Liver	1.000	✓	✓	
Lung_L	0.250	✓		
Lung_R	0.250	✓		
- CTV		-		

ternal Regio	ternal Regions of Interest Defaults										
ROI Name	Density	Visible by default	Do not import	Pseudonyms							
BODY	1.000	✓		EXTERNAL							

Use External defined by planning system, if presen

Use Planning System External over External ROI List, if both are presen

Use External ROI List over Planning System External, if both are present


If density is specified in the plan, use it instead of ROI Preset

Automatic Density Assignments

- Radcalc ROI module recognizes and matches imported structures names matching the TG-263 standardized OAR names in the configuration utility
- Default densities, visibility for structures can be set
- No need for pseudonyms

MIM Maestro

- MIM Maestro custom workflows configured to load "SBRT Lung" ROI templates using TG-263 standardized ROI nomenclature
- Deployment of MIM at all Rad. Therapy centers promotes standardization across platforms



RapidPlan

Standardized nomenclature simplifies the matching of structures to the RapidPlan template

A	dd Plan COURSE1 / Pelvis BST	to DVH Estima	tion Model - Wing	o, Haywood (17250)				
## 2.0 cn		Model ID						2
ning) Brachyt		Prostate	e - UC San Diego	p Pelv	s Thurs	day, March 28, 2019	1:50:49 PM	•
Unapproved -	Model Version	40.0.00						- CT_Pelvis
•]		Pelvis						€ ^H X
	Trained Published							\$1 c
			than (JROGER2	3) Thursday, March 28, 2019	1:50:49 PM			
			blished 11-04-2	016 (kevinmoore@ucsd.edu), Marie	Cornell CMD (mcorr	ell@uced.edu)		and the second
			gebasedrt.org	Kevininoore@ucsu.edu), mane	Conten, CIMD (Incon	ien@dcsd.edd)		
		Clinical Desc	cription					
								101.7
		3240.0	cGy					A second s
	Plan Structure ID (C	Codes)	Туре	Model Structure ID (Codes)	Target Dose			
7.0.00 -	Bladder (15900)		ORGAN	BLADDER (15900)		Femur_L,	Femur_R	E F
Unapproved -	Bladder sub PTV (1	15900)	ORGAN	BLADDER (15900)				
	BODY (BODY)		EXTERNAL					H
	CTV LNs L (Contro)I)	сти					
	CTV LNs R (Contro	ol)	сти			=		
	CTV_LN combined	I (CTV_Interm	сти					
	Femoral Head Lt (5	55012)	ORGAN					Here I
	Femoral Head Rt (55011)	ORGAN					105.
-	Penile Bulb (19614		ORGAN	PenileBulb (19614)				
Y: 0.00 c	Prostate (9600)		сти					
Optimizati	PTV 77.4 (PTV_Hi	gh)	PTV	PTV (PTV_High)	▼ 3240.0 cGy			
MLC	PTV_45 PELVIS (F	PTV_Intermed	PTV					
VMAT VMAT	PTV+1 (PRV)		ORGAN					1.7 0.00 1.7 0.00
						÷		5.0 0.00
							Cancel	5.0 0.00 5.0 0.00
						- Contraction of the second se	Lancor	5.0 0.00

Clinical Description Publishing Log					Edit Model and	Structures		7		N/A		Ļ
Technical Description Training Log							9		N/A			
								10		N/A		
Model Structures and Objectives								11		N/A		
- Target ID	Vol [%]	Dose		Priority	gEUD a		•	15		N/A		
Lower	100.0	97.0	%	150				16		N/A		
Lower	98.0	100.0	%	150				23		N/A		
BLADDER (15900))							24		N/A		
Upper (fixed dose, generated vol.)	Generated	95.0	%	80]	х		ΡΤ	/: DV	'H plot		
Upper (fixed dose, generated vol.)	Generated	50.0	%	80]	х	=					
Upper (fixed dose, generated vol.)	Generated	25.0	%	30					100.0			
Line (preferring target)	Generated	Genera	ted	Generate	i				80.0			
Femur_L (24475	5)							(%)				
Line (preferring target)	Generated	Genera	ted	Generate	1	х		Relative Volume (%)	60.0			
Femur_R (24474	9							ve Vo	0			
Line (preferring target)	Generated	Genera	ted	Generate	i	x		Relati	40.0			
PenileBulb (19614	Ð								20.0			
Line (preferring target)	Generated	Genera	ted	Generate	1	x	Ţ					
Normal Tissue Objective									0.0	0.0	10.0	20.
 Smoothing Parameters (for IMRT) 											10.0	20.

Conclusions

- Use of TG-263's standardized nomenclature has reduced variation across users at multiple facilities
- Efficiencies in the planning and plan documentation processes were realized when users employed customized templates based on TG-263 standardized nomenclature across multiple software systems
- Utilization and compliance with TG-263 templates using standardized nomenclature has been observed in all LCI clinics



Conclusions



- TG-263's standardized nomenclature recommendations can be incorporated into the tx planning process across a number of software platforms
- The medical physicist can serve as a leader or contributor to an effective implementation strategy incorporating varied practice stakeholders

Thanks to Levine Cancer Institute:

- Physicists
- Radiation Oncologists
- Dosimetrists
 - Robyn Walker, CMD
 - Holly Fletcher